Olumiant’s limited U.S. approval won’t dent the drug maker’s narrow moat.
Vertex Pharmaceutical's monopoly in the cystic fibrosis market forms the basis of our narrow-moat rating, and we expect that moat to continue to grow.
The shares currently look undervalued ahead of further drug approval.
Based on the stellar results and clean safety profile, we think patisiran will likely receive approval in the U.S. and Europe in 2018, which drives our fair value change and peak sales estimates near $1 billion.
The letter the drugmaker sent to prescribers about Ocaliva didn't include any new information, yet it fed market fears about the drug's commercial potential.
The string of severe adverse events with Ionis' inotersen program puts competitor Alnylam in a more favorable position.
The firm's key program for treating NASH is well positioned, but the space is becoming increasingly crowded.
Shares soared following favorable news from the narrow-moat drugmaker's pivotal trials, yet we see further upside.
The market is underestimating Vertex's entrenched position in the cystic fibrosis market supported by a robust pipeline of next-generation products.
The merger between the medical clinical trial companies has created some upside for the stock.
Though we've lowered our fair-value estimate of the drugmaker after it announced that it has stopped development of a key drug, we still believe in the potential of Alnylam’s remaining pipeline.
Despite a slowdown in Orkambi refills, this narrow-moat drugmaker's burgeoning cystic fibrosis portfolio should create a dominant franchise in this lucrative rare disease market.